Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Cytokinetics, Inc.COM | COM | $83,519,594 | 34.5% |
| Zenas Biopharma, Inc..COM | COM | $60,611,247 | 25.1% |
| Kailera TherapeuticsCOM | COM | $54,091,515 | 22.4% |
| Biohaven LtdCOM | COM | $43,695,224 | 18.1% |
- Class
- COM
- Share
- 34.5%
- Class
- COM
- Share
- 25.1%
- Class
- COM
- Share
- 22.4%
- Class
- COM
- Share
- 18.1%
The share class is shown on a wider screen.
The 4 largest of 4 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 2081668
- File number
- 028-26787
- Options
- 0 call, 0 put
- In the 25 largest
- 100.0%
- Prior quarter
- $172,764,205 at 31 March 2026
- Positions opened
- 1
- Positions closed
- 1
Common questions
What are Royalty Pharma Sub-Manager’s 13F holdings worth?
$241,917,580 across 4 positions for the quarter ended 30 June 2026.
What is Royalty Pharma Sub-Manager’s largest 13F holding?
CYTOKINETICS, INC (COM) was the largest position at $83,519,594, or 34.5% of reported 13F value, as of 30 June 2026.
How concentrated is Royalty Pharma Sub-Manager’s 13F portfolio?
The ten largest positions accounted for 100.0% of reported value and the twenty-five largest for 100.0%, across 4 positions as of 30 June 2026.
Does Form 13F show everything Royalty Pharma Sub-Manager manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Royalty Pharma Sub-Manager file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.